Trevi Therapeutics (NASDAQ:TRVI) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a report released on Monday morning,Benzinga reports. HC Wainwright currently has a $21.00 price objective on the stock.

TRVI has been the subject of several other research reports. B. Riley Financial upgraded Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, November 17th. Morgan Stanley upped their price objective on Trevi Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. D. Boral Capital reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Trevi Therapeutics in a research note on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Wednesday, January 21st. Finally, Leerink Partners boosted their target price on Trevi Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $21.10.

Trevi Therapeutics Stock Down 12.0%

Trevi Therapeutics stock opened at $11.70 on Monday. The company’s 50-day moving average price is $11.24 and its 200-day moving average price is $10.76. The company has a market cap of $1.50 billion, a PE ratio of -31.62 and a beta of 0.94. Trevi Therapeutics has a twelve month low of $4.85 and a twelve month high of $14.39.

Institutional Investors Weigh In On Trevi Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. AQR Capital Management LLC lifted its stake in shares of Trevi Therapeutics by 20.4% during the 1st quarter. AQR Capital Management LLC now owns 27,720 shares of the company’s stock worth $174,000 after acquiring an additional 4,688 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Trevi Therapeutics by 31.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,143 shares of the company’s stock valued at $278,000 after acquiring an additional 10,445 shares during the period. Millennium Management LLC boosted its holdings in Trevi Therapeutics by 356.3% during the 1st quarter. Millennium Management LLC now owns 823,249 shares of the company’s stock valued at $5,178,000 after acquiring an additional 642,830 shares during the period. Strs Ohio bought a new position in Trevi Therapeutics in the 1st quarter valued at $52,000. Finally, Los Angeles Capital Management LLC bought a new position in Trevi Therapeutics in the 2nd quarter valued at $90,000. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Trevi Therapeutics News Summary

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Trevi completed an end‑of‑Phase 2 meeting with the FDA and said it has gained alignment on its development program for idiopathic pulmonary fibrosis (IPF)‑related chronic cough; the company will run two Phase 3 trials of nalbuphine ER — a meaningful de‑risking step and a clear clinical catalyst. Article Title
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and set a $21 price target (roughly +79.5% vs. the $11.70 reference), providing analyst support that can attract momentum buyers. Article Title
• Positive Sentiment: D. Boral Capital also reaffirmed a “buy” and set a $19 price target (about +62% upside from the $11.70 reference), adding further institutional endorsement. Article Title
• Neutral Sentiment: TRVI was highlighted by a Zacks piece as one of three stocks showing momentum that could lead to a breakout in March — a market‑attention note that can amplify moves but is not a company‑specific fundamental change. Article Title
• Neutral Sentiment: Trevi is expected to report quarterly earnings on Tuesday — an event that could add short‑term volatility depending on guidance or cash‑balance commentary. Article Title
• Negative Sentiment: The stock dipped after the company said it plans parallel trials in a lung disease program, prompting investor concerns around complexity and timelines; Stifel pushed back on the timeline worries, but the initial reaction was negative. Article Title

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.